Expert Analysis: ASCO GI 2023

CME

CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 23, 2023

Expiration: March 22, 2024

Activity

Progress
1
Course Completed
References

  1. Cao W, Xing H, Li Y, et al. Claudin 18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:1-21.
  2. Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinaoma. Ann Oncol. 2021;32:609-619.
  3. Shitara K, Lordick F, Bang Y-J, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+)/HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary results from phase 3 SPOTLIGHT study. Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract LBA292.
  4. Trifluridine and tipiracil [prescribing information]. Princeton, NJ: Taiho Oncology, Inc.; 2019.
  5. Yoshida Y, Yamada T, Kamiyama H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol. 2021;26:111-117. Tabernero J, Prager GW, Fakih M, et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study. Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract 4.
  6. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. v.3.2022. nccn.org. Accessed March 7, 2023.
  7. Irinotecan liposome injection [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2017.
  8. Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract LBA661.
  9. Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I/II study. Eur J Cancer. 2021;151:14-24.
  10. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med. 2010;362:1273-1281.
  11. Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM 2022;1:1-11.
  12. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers. JAMA Oncol. 2019;5:824-830.
  13. Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract LBA490.
  14. Maithel SK, Javle MM, Mahipal A, et al. NEO-GAP: a phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2022. Abstract 4097.
  15. Kato K, Ajani JA, Doki Y, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. Presented at: 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract 290.
  16. Janjigian YY, Shitara K, Moehler MH, et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract 291.
  17. Yanez PE, Ben-Aharon I, Rojas C, et al. First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): safety run-in results. Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract 411.
  18. Ciombor KK, Zemla TJ, Hubbard JM, et al. A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR Presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2023. Abstract 139.
  19. Tucatinib [prescribing information]. Bothell, WA: Seagen, Inc.; 2023.
  20. Strickler J, Cercek A, Siena S, et al. Primary analysis of MOUNTAINEER: a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. Presented at: European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract LBA-2.